<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page_2_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page_2_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer</o:LastAuthor>
  <o:Revision>24</o:Revision>
  <o:TotalTime>46</o:TotalTime>
  <o:Created>2003-07-03T13:12:00Z</o:Created>
  <o:LastSaved>2003-07-22T09:43:00Z</o:LastSaved>
  <o:Pages>3</o:Pages>
  <o:Words>742</o:Words>
  <o:Characters>4231</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>35</o:Lines>
  <o:Paragraphs>8</o:Paragraphs>
  <o:CharactersWithSpaces>5195</o:CharactersWithSpaces>
  <o:Version>9.4402</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>150</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:navy;
	mso-ansi-language:FI;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1030"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" alt=""
 href="../archive.html" title="To Protein Archive"
 style='position:absolute;margin-left:0;margin-top:0;width:113.5pt;height:36.5pt;
 z-index:1;mso-position-horizontal:left;mso-position-horizontal-relative:text;
 mso-position-vertical:top;mso-position-vertical-relative:line' o:allowoverlap="f"
 o:button="t">
 <v:fill o:detectmouseclick="t"/>
 <v:imagedata src="interpro_pom_logo.jpg"/>
 <w:wrap type="square" anchorx="page"/>
</v:shape><![endif]--><![if !vml]><a
href="http://www.ebi.ac.uk/interpro/protein_focus.html"><img border=0 width=151
height=49
src="interpro_pom_logo.jpg"
align=left hspace=12 title="To Protein Archive" v:shapes="_x0000_s1026"></a><![endif]><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a><a
href="http://www.ebi.ac.uk/interpro/index.html"></a></p>

<h1 align=center style='text-align:center'><span lang=FI style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy;mso-ansi-language:FI'>SRC, proto-oncogene
tyrosine-protein kinase<o:p></o:p></span></h1>

<p class=MsoNormal><span lang=FI style='font-size:28.0pt;mso-bidi-font-size:
12.0pt;mso-ansi-language:FI'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal><span lang=FI style='font-size:28.0pt;mso-bidi-font-size:
12.0pt;mso-ansi-language:FI'><!--[if gte vml 1]><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:415.5pt;height:258pt'>
 <v:imagedata src="./Page_2_files/image001.jpg" o:title="Src_activation"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=554 height=344
src="./Page_2_files/image002.jpg" v:shapes="_x0000_i1025"><![endif]><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>Src
regulation: conformational opening and activation<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>Reprinted
from Biochim Biophys Acta 1602(2), M. Frame, <i>Src in Cancer</i>, 114-130, 2002,
with permission from Elsevier, </span><a
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12020799&amp;dopt=Abstract&amp;tool=iconabstr"
title="M. Frame (2002) Biochim Biophys Acta 1602(2):114-30.  Src in cancer: deregulation and consequences for cell behaviour">PMID:
12020799</a></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span lang=EN-US style='color:navy;mso-ansi-language:EN-US'>How Src works<o:p></o:p></span></h1>

<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'><span
style='mso-tab-count:1'>            </span></span>The Src protein has three
major domains, SH2 (for Src homology 2), SH3, and the kinase catalytic domain
(or SH1), as shown above.<span style="mso-spacerun: yes">  </span>SH2 and SH3
both play a part in protein-protein interactions, while the kinase catalytic
domain contains the kinase active site.<span style="mso-spacerun: yes"> 
</span>Src can be switched from an inactive to an active state through control
of its phosphorylation state, or through protein interactions.<span
style="mso-spacerun: yes">  </span>There are two major phosphorylation sites on
Src:<span style="mso-spacerun: yes">  </span>one is at Tyr416 (or Y416), the other
at Tyr527, as marked in the drawing above for chicken Src.<span
style="mso-spacerun: yes">  </span>Tyr416 can be auto-phosphorylated, which
activates Src by displacing the P-Tyr416 from the binding pocket, allowing the
substrate to gain access.<span style="mso-spacerun: yes">  </span>A more
critical site is Tyr527, which can be phosphorylated and dephosphorylated by
various proteins, such as CSK kinase (phosphorylates), or SHP-1 phosphorylase
(dephosphorylates).<span style="mso-spacerun: yes">  </span>Phosphorylation of
Tyr527 inactivates Src through the interaction of P-Tyr527 with the SH2 domain,
which effectively folds Src up into a closed, inaccessible bundle.<span
style="mso-spacerun: yes">  </span>Dephosphorylation of Tyr527 releases this
bond, opening up the molecule to an active state.<span style="mso-spacerun:
yes">  </span>Protein interactions also act to regulate Src by either directly
activating Src, or by moving Src to sites of action.<span style="mso-spacerun:
yes">  </span>Both platelet-derived growth factor and focal adhesion kinase are
able to bind to the SH2 domain, causing Src to open up into the active form.</p>

<p class=MsoNormal style='text-indent:36.0pt'>Many of the substrates that Src
can phosphorylate with its kinase domain form part of signalling cascades.<span
style="mso-spacerun: yes">  </span>These include Fak and Cas, which are
important for integrin signalling, as well as Shc and Stat3, which are involved
in growth regulation.<span style="mso-spacerun: yes">  </span>Signalling
systems often involve a cascade mechanism of sequential phosphorylation and
dephosphorylation of proteins in the cascade, as occurs here.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span lang=EN-US style='color:navy;mso-ansi-language:EN-US'>Src family
members<o:p></o:p></span></h1>

<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'>Considering the vital role Src
seems to play in cell signalling, scientists were surprised to find that mice
deficient in Src could survive.<span style="mso-spacerun: yes">  </span>The
reason for this result is that Src is one of nine members in a closely-related
family that can often compensate for one another.<span style="mso-spacerun:
yes">  </span>Other Src family kinase members are Fyn and Yes, which like Src
are widely expressed, and Blk, Fgr, Hck, Lck, Lyn, and Yrk, which are expressed
in specific tissues.<span style="mso-spacerun: yes">  </span>All these proteins
have structurally similar SH2, SH3 and kinase domains and are capable of acting
as signalling molecules in a similar manner to Src.<span lang=EN-US
style='color:navy;mso-ansi-language:EN-US'><span style='mso-tab-count:1'>      </span><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-US style='color:navy;mso-ansi-language:EN-US'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<h1><span style='color:navy'>When Src goes wrong<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>Under
normal circumstances, Src is predominantly inactive in cells, being switched on
only at specific times.<span style="mso-spacerun: yes">  </span>However, if the
fine balance between phosphorylation and dephosphorylation is disrupted,
changes can occur in Src activity with drastic results.<span
style="mso-spacerun: yes">  </span>Several cancers, including colon and breast
cancer, have been associated with an increase in Src activity.<span
style="mso-spacerun: yes">  </span>In fact, Src was first isolated as an
oncogene, v-Src, from the transforming virus, Rous Sarcoma Virus.<span
style="mso-spacerun: yes">  </span>v-Src was found to lack the region of the
cellular protein (c-Src) that contains Tyr527, making it continually active.</p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>In a
similar fashion, c-Src can become abnormally active, either through mutations
in c-Src itself, or through mutations in proteins that regulate c-Src.<span
style="mso-spacerun: yes">  </span>In late stage colon cancers, mutations have
been reported in the src gene that cause the loss of the region containing
Tyr527, leading to Src over-activity.<span style="mso-spacerun: yes"> 
</span>Proteins that regulate Src have also been found at abnormal levels in
cancer cells, including both those that activate and those that inactivate Src.<span
style="mso-spacerun: yes">  </span>Proteins such as PTPalpha, SHP-1 and PTP1B
that activate Src by dephosphorylating Tyr527 have been detected at elevated
levels in various cancer cells, including epidermal and breast carcinoma
cells.<span style="mso-spacerun: yes">  </span>Conversely, proteins such as Csk
and Chk that inactivate Src by phosphorylation of Tyr527 have been detected at
reduced levels in certain cancer cells.<span style="mso-spacerun: yes"> 
</span>As such, proteins like Csk and Chk are considered to have a
tumour-suppressing ability. </p>

<p class=MsoNormal><span style='mso-tab-count:1'>            </span>With its
importance in cell regulation, and its implication in cancer, Src, as well as
other protein kinases, has become an important drug target in the battle
against cancer.<span style='color:navy'><o:p></o:p></span></p>

<p class=MsoNormal style='text-indent:36.0pt'><span lang=EN-US
style='color:navy;mso-ansi-language:EN-US'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<h2 align=center style='text-align:center'><span style='font-style:normal'>Next:<span
style="mso-spacerun: yes">  </span><a href="Page_3.htm">What InterPro tells us</a><o:p></o:p></span></h2>

<h2 align=center style='text-align:center'><span style='font-style:normal'>Previous:<span
style="mso-spacerun: yes">  </span><a href="Page_1.htm">Src, a key regulator</a><o:p></o:p></span></h2>

</div>

</body>

</html>
